How do I install the Endo Prefer Nsaid Dmard skill?

Run npx skillmds@latest add dromlakhani/endo-prefer-nsaid-dmard in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Prefer Nsaid Dmard safe to use?

SkillMD's automated safety review verdict for this skill is PASS. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Prefer Nsaid Dmard?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Prefer Nsaid Dmard free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Prefer Nsaid Dmard?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Prefer Nsaid Dmard by dromlakhani

Name: Endo Prefer Nsaid Dmard
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Endo Prefer Nsaid Dmard

Recommends using NSAIDs or DMARDs instead of glucocorticoids for chronic inflammatory disease (e.g., rheumatoid arthritis) to limit weight gain. Triggered when clinicians ask, “What anti‑inflammatory should I choose for this RA patient to avoid weight gain?” or “Should I avoid steroids in this obese patient with RA?”

dromlakhani Updated Aug 19, 2026 10 repo stars

File contents

Prefer NSAIDs/DMARDs over corticosteroids in chronic inflammatory disease to avoid weight gain

STEP 1 — Gather Information

Collect diagnosis of chronic inflammatory disease (e.g., RA), disease activity score, comorbidities (obesity, diabetes, hypertension, CKD, GI disease), current medications, contraindications to NSAIDs/DMARDs (active ulcer, CKD stage 4‑5, heart failure, immunosuppression need), baseline weight/BMI, and patient preferences.
Action: Proceed to assess suitability for NSAID/DMARD therapy.

STEP 2 — Rule In / Rule Out

Is there a contraindication to NSAIDs or DMARDs (e.g., active peptic ulcer, eGFR < 30 mL/min, NYHA III‑IV heart failure, need for ongoing immunosuppression)?

Yes: Rule out NSAID/DMARD; consider low‑dose glucocorticoid with bone‑protective measures or alternative steroid‑sparing agent.
No: Rule in NSAID/DMARD as preferred option.
Decision: Choose pathway based on contraindication status.

STEP 3 — Classify or Stratify

Stratify by disease severity and prognostic features: mild/moderate disease without poor prognostic factors → start NSAID; moderate‑to‑severe disease, high disease activity, or presence of erosions → start conventional DMARD (e.g., methotrexate).
Decision: Select NSAID for mild/moderate cases; select DMARD for more active or high‑risk disease.

STEP 4 — Decide

Prescribe the chosen NSAID (e.g., ibuprofen 600 mg q6h PRN, naproxen 500 mg BID) or DMARD (e.g., methotrexate 15 mg weekly with folic acid), schedule follow‑up in 4–6 weeks to assess pain, inflammation, weight change, and adverse effects, and educate patient on weight monitoring and lifestyle measures.
Action: Initiate therapy and arrange reassessment.

Clinical Guardrails / Mimics / Pitfalls

Avoid long‑term glucocorticoids as first line solely for weight concerns; monitor for GI bleeding, renal impairment, and hypertension with NSAIDs; obtain LFTs and CBC before and during methotrexate; do not stop glucocorticoids abruptly if patient already on them — taper while introducing steroid‑sparing agent; consider cardioprotective NSAID (e.g., celecoxib ) in high‑dose naproxen) in patients with cardiovascular risk.

Clinical Clinical Example

A 58‑year‑old woman with rheumatoid arthritis, BMI 32, mild joint pain, normal renal and hepatic function, no ulcer history, asks which anti‑inflammatory will limit weight gain. No NSAID contraindication → prescribe ibuprofen 600 mg q6h PRN, add methotrexate 15 mg weekly if symptoms persist at 4‑week visit, counsel on weight tracking and diet/exercise.

Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

---name: endo-prefer-nsaid-dmarddescription: Recommends using NSAIDs or DMARDs instead of glucocorticoids for chronic inflammatory disease (e.g., rheumatoid arthritis) to limit weight gain. Triggered when clinicians ask, “What anti‑inflammatory should I choose for this RA patient to avoid weight gain?” or “Should I avoid steroids in this obese patient with RA?”---# Prefer NSAIDs/DMARDs over corticosteroids in chronic inflammatory disease to avoid weight gain## STEP 1 — Gather InformationCollect diagnosis of chronic inflammatory disease (e.g., RA), disease activity score, comorbidities (obesity, diabetes, hypertension, CKD, GI disease), current medications, contraindications to NSAIDs/DMARDs (active ulcer, CKD stage 4‑5, heart failure, immunosuppression need), baseline weight/BMI, and patient preferences. **Action:** Proceed to assess suitability for NSAID/DMARD therapy.## STEP 2 — Rule In / Rule OutIs there a contraindication to NSAIDs or DMARDs (e.g., active peptic ulcer, eGFR < 30 mL/min, NYHA III‑IV heart failure, need for ongoing immunosuppression)? - **Yes:** Rule out NSAID/DMARD; consider low‑dose glucocorticoid with bone‑protective measures or alternative steroid‑sparing agent. - **No:** Rule in NSAID/DMARD as preferred option. **Decision:** Choose pathway based on contraindication status.## STEP 3 — Classify or StratifyStratify by disease severity and prognostic features: mild/moderate disease without poor prognostic factors → start NSAID; moderate‑to‑severe disease, high disease activity, or presence of erosions → start conventional DMARD (e.g., methotrexate). **Decision:** Select NSAID for mild/moderate cases; select DMARD for more active or high‑risk disease.## STEP 4 — DecidePrescribe the chosen NSAID (e.g., ibuprofen 600 mg q6h PRN, naproxen 500 mg BID) or DMARD (e.g., methotrexate 15 mg weekly with folic acid), schedule follow‑up in 4–6 weeks to assess pain, inflammation, weight change, and adverse effects, and educate patient on weight monitoring and lifestyle measures. **Action:** Initiate therapy and arrange reassessment.## Clinical Guardrails / Mimics / PitfallsAvoid long‑term glucocorticoids as first line solely for weight concerns; monitor for GI bleeding, renal impairment, and hypertension with NSAIDs; obtain LFTs and CBC before and during methotrexate; do not stop glucocorticoids abruptly if patient already on them — taper while introducing steroid‑sparing agent; consider cardioprotective NSAID (e.g., celecoxib ) in high‑dose naproxen) in patients with cardiovascular risk.## Clinical Clinical ExampleA 58‑year‑old woman with rheumatoid arthritis, BMI 32, mild joint pain, normal renal and hepatic function, no ulcer history, asks which anti‑inflammatory will limit weight gain. No NSAID contraindication → prescribe ibuprofen 600 mg q6h PRN, add methotrexate 15 mg weekly if symptoms persist at 4‑week visit, counsel on weight tracking and diet/exercise.**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

Frequently asked questions